| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| Targets |
Caspase-1 IL-1β
|
|---|---|
| ln Vitro |
Ac-YVAD-CHO acetate suppresses human and mouse IL-1β with IC50 values of 2.5 and 0.7 μM, respectively [1]. The rise in IL-1β in LPS-treated plasma and peritoneal fluid can be decreased by Ac-YVAD-CHO (0.01-100 μM) acetate [1]. Thymocyte apoptosis mediated by NO is decreased by Ac-YVAD-CHO (15.6 μM) acetate [3]. In thymocytes treated with SNAP, Ac-YVAD-CHO (15.6 μM, 12 hours) acetate prevents NO-induced PARP cleavage [3].
|
| ln Vivo |
Ac-YVAD-CHO (30 mg/kg; intraperitoneal; 6 hours) In the blood of mice sensitive to P. acnes, acetate lowers the levels of IL-1β [1]. Intrastriatal infusion of Ac-YVAD-CHO (2–8 μg) Rat striatal apoptosis induced by quinolinic acid (QA) is attenuated by acetate [2]. Ac-YVAD-CHO (i.p., 10 and 50 mg/kg for one hour). Acetate is quickly removed from the circulation and drops dramatically to between 1 and 0.2 μM at 30 and 60 minutes after injection [2].
|
| Cell Assay |
Western Blot Analysis[3]
Cell Types: SNAP-treated thymocytes Tested Concentrations: 15.6 μM Incubation Duration: 12 h Experimental Results: decreased PARP cleavage. |
| Animal Protocol |
Animal/Disease Models: P. acnes-sensitized mice[1]
Doses: 50 mg/kg Route of Administration: Ip Experimental Results: Suppressed IL-1β levels in blood. Animal/Disease Models: Quinolinic acid-treated Rats[2] Doses: 2-8 μg Route of Administration: Intrastriatal infusion. Experimental Results: Attenuated Quinolinic acid (QA)-induced increases in p53 and apoptosis in rat striatum. Inhibited QA-induced increases in caspase-1 activity and p53 protein levels, with no effect on QA-induced IκB-α degradation, NF -κB or AP-1 activation. |
| References |
|
| Molecular Formula |
C25H36N4O10
|
|---|---|
| Related CAS # |
Ac-YVAD-CHO;143313-51-3
|
| Appearance |
Typically exists as solid at room temperature
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
|---|
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
